Amphivena Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.amphivena.com
Study of AMV564 in Subjects With Advanced Solid Tumors
Phase 1
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- Biological: AMV564
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Amphivena Therapeutics, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04128423
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Phase 1
Completed
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- Drug: AMV564 14-Day CIV
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Amphivena Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03516591
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Washington University, Siteman Cancer Center, Saint Louis, Missouri, United States
Study of AMV564 in Patients With AML
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: AMV564Combination Product: AMV564 in combination with pembrolizumab
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Amphivena Therapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03144245
- Locations
- 🇺🇸
Northwestern, Chicago, Illinois, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath